Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

VYGR

Voyager Therapeutics Inc

May 02 • 11:28AM ET

8.31

Dollar change -0.05
Percentage change -0.60	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM AVUV IWO IBB VTWO FDM LABU IWC

Index	RUT	P/E	2.69	EPS (ttm)	3.09	Insider Own	18.20%	Shs Outstand	54.30M	Perf Week	11.99%
Market Cap	451.23M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	-0.42%	Shs Float	44.42M	Perf Month	-11.12%
Income	132.33M	PEG	-	EPS next Q	-0.44	Inst Own	48.62%	Short Float	7.80%	Perf Quarter	9.92%
Sales	250.01M	P/S	1.80	EPS this Y	-160.51%	Inst Trans	0.50%	Short Ratio	5.27	Perf Half Y	26.48%
Book/sh	5.37	P/B	1.55	EPS next Y	2.35%	ROA	51.83%	Short Interest	3.46M	Perf Year	19.74%
Cash/sh	4.25	P/C	1.95	EPS next 5Y	-	ROE	89.61%	52W Range	6.06 - 14.34	Perf YTD	-1.54%
Dividend Est.	-	P/FCF	6.04	EPS past 5Y	-	ROI	52.22%	52W High	-42.05%	Beta	1.03
Dividend TTM	-	Quick Ratio	4.96	Sales past 5Y	355.29%	Gross Margin	98.22%	52W Low	37.13%	ATR (14)	0.43
Dividend Ex-Date	-	Current Ratio	4.96	EPS Y/Y TTM	366.44%	Oper. Margin	48.80%	RSI (14)	50.48	Volatility	5.01% 4.36%
Employees	162	Debt/Eq	0.09	Sales Y/Y TTM	511.18%	Profit Margin	52.93%	Recom	1.30	Target Price	17.78
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	304.11%	Payout	0.00%	Rel Volume	0.50	Prev Close	8.36
Sales Surprise	336.50%	EPS Surprise	532.53%	Sales Q/Q	5910.39%	Earnings	Feb 28 AMC	Avg Volume	657.00K	Price	8.31
SMA20	1.69%	SMA50	-5.48%	SMA200	1.40%	Trades		Volume	109,801	Change	-0.60%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-24	Initiated	Guggenheim	Buy	$22
Mar-19-24	Initiated	H.C. Wainwright	Buy	$30
Mar-07-24	Initiated	Citigroup	Buy	$16
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$14
May-10-23	Initiated	Truist	Buy	$18
Mar-10-23	Initiated	Oppenheimer	Outperform	$14
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform	$6 → $9
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral	$18 → $6
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral	$6
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$15 → $10
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$10
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform	$28 → $17
Mar-19-20	Initiated	The Benchmark Company	Buy	$18
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy	$32
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight

Show Previous Ratings

Apr-22-24 04:30PM	Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting (GlobeNewswire)
Apr-16-24 07:00AM	Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment (GlobeNewswire)
Mar-30-24 03:00AM	Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs. (Barrons.com)
Mar-26-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.21%
Mar-13-24 07:00AM	Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer (GlobeNewswire)
01:09PM	Loading…
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 11:09AM	Q4 2023 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.25%
09:54AM	Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:41PM	Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position (GuruFocus.com)
04:32PM	Voyager Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results (GlobeNewswire)
Feb-26-24 07:00AM	Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment (GlobeNewswire) +5.62%
Feb-21-24 07:00AM	Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Feb-20-24 07:00AM	Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research (GlobeNewswire)
Feb-07-24 07:00AM	Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference (GlobeNewswire)
10:09PM	Loading…
Jan-11-24 10:09PM	Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024 (InvestorPlace)
Jan-04-24 10:45PM	Voyager Therapeutics Announces Pricing of Public Offering (GlobeNewswire)
04:14PM	Voyager Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Jan-03-24 11:15AM	Voyager (VYGR) Gains on Gene Therapy Deal With Novartis (Zacks) +19.67%
07:00AM	Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 04:07PM	Novartis Sweetens Its Deal With Voyager, And VYGR Stock Flashes A Bullish Sign (Investor's Business Daily) +6.64%
01:51PM	Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments (Investopedia)
10:46AM	VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today (InvestorPlace)
07:36AM	UPDATE 2-Novartis signs gene therapy deal with Voyager for $100 mln upfront (Reuters)
07:14AM	Voyager Therapeutics shares jump after $1.2 billion deal with Novartis (Reuters)
07:14AM	Novartis signs gene therapy deal with Voyager for $100 mln upfront (Reuters)
07:09AM	Novartis deepens ties with Voyager via $100M gene therapy deal (BioPharma Dive)
07:00AM	Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies (GlobeNewswire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-08-23 10:13AM	12 Best Healthcare Stocks For the Long-Term (Insider Monkey)
06:10AM	Loading…
Dec-07-23 06:10AM	Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme (Pharmaceutical Business Review)
Dec-06-23 07:00AM	Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program (GlobeNewswire)
Nov-07-23 10:16AM	Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.08%
Nov-06-23 05:22PM	Voyager Therapeutics Inc (VYGR) Reports Q3 2023 Financial Results (GuruFocus.com)
04:17PM	Voyager Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Oct-30-23 07:00AM	Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Sep-25-23 07:00AM	Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference (GlobeNewswire)
Sep-07-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-23 07:00AM	Voyager Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-23 08:14AM	11 Most Undervalued Biotech Stocks to Buy According to Analysts (Insider Monkey)
Aug-08-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-23 08:00AM	Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer (GlobeNewswire)
Aug-03-23 08:25AM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Voyager Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results (GlobeNewswire)
Aug-02-23 07:00AM	Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference (GlobeNewswire)
Jul-27-23 07:00AM	Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Jul-14-23 05:40AM	2 Biotech Stocks That Could Make You Richer (Motley Fool)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-23 08:00AM	Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (GlobeNewswire)
Jun-21-23 04:49AM	Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last? (Zacks) -9.65%
Jun-15-23 06:30AM	Investors in Voyager Therapeutics (NASDAQ:VYGR) have seen stellar returns of 168% over the past year (Simply Wall St.)
Jun-01-23 07:52PM	The 7 Best Stocks Under $15 to Buy in June 2023 (InvestorPlace)
07:00AM	Voyager Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 12:29PM	Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock's On An Uptrend: Are Strong Financials Guiding The Market? (Simply Wall St.) -8.79%
May-18-23 06:00AM	Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER-Generated Novel Capsids at the ASGCT 26th Annual Meeting (GlobeNewswire)
May-09-23 08:35AM	Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates (Zacks) +29.48%
07:37AM	Voyager Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results (GlobeNewswire)
06:55AM	Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors (GlobeNewswire)
May-05-23 06:08AM	Revenues Working Against Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Share Price (Simply Wall St.)
May-03-23 10:25PM	Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains? (Zacks) +11.10%
May-02-23 04:30PM	Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire)
07:00AM	Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Apr-08-23 09:12AM	Companies Like Voyager Therapeutics (NASDAQ:VYGR) Can Afford To Invest In Growth (Simply Wall St.)
Mar-28-23 07:00AM	Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimers Disease and GBA1 Gene Therapy Program for Parkinsons Disease at the AD/PD Conference (GlobeNewswire)
Mar-12-23 08:04AM	Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) top owners are individual investors with 29% stake, while 23% is held by institutions (Simply Wall St.)
Mar-08-23 03:03AM	Q4 2022 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.76%
Mar-07-23 08:25AM	Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.79%
07:00AM	Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results (GlobeNewswire)
Mar-06-23 07:00AM	Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets (GlobeNewswire) +8.89%
Feb-28-23 07:00AM	Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast (GlobeNewswire)
Feb-13-23 08:00AM	Zacks.com featured highlights include Las Vegas Sands, Voyager Therapeutics and nCino (Zacks)
Feb-10-23 06:23AM	3 Best Stocks to Invest in for Remarkable Earnings Acceleration (Zacks)
Feb-09-23 07:00AM	Voyager Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-03-23 04:36AM	Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock? (Zacks) -8.78%
Feb-02-23 06:43AM	Daily Vickers Top Buyers & Sellers for 02/02/2023 (Argus Research) -5.13%
Jan-27-23 07:00AM	Daily Vickers Top Buyers & Sellers for 01/27/2023 (Argus Research)
Jan-24-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:15AM	7 A-Rated Stocks to Buy for Less Than $25 (InvestorPlace)
Jan-20-23 12:08PM	Why Voyager Therapeutics Stock Is Sinking This Week (Motley Fool)
09:55AM	Voyager Therapeutics (VYGR)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Jan-09-23 01:23PM	Voyager, Neurocrine sign new deal worth up to $4.4B (American City Business Journals)
09:15AM	Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies (Benzinga)
08:15AM	Voyager, Neurocrine ink gene-therapy deal (MarketWatch)
07:00AM	Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyagers GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases (GlobeNewswire)
Jan-04-23 07:00AM	Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 06:57AM	Those who invested in Voyager Therapeutics (NASDAQ:VYGR) a year ago are up 106% (Simply Wall St.)
Dec-14-22 07:00AM	Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors (GlobeNewswire) -6.56%
Nov-29-22 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 05:26AM	Voyager Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-08-22 08:25AM	Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates (Zacks) +9.60%
07:00AM	Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results (GlobeNewswire)
Nov-01-22 07:30AM	Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast (GlobeNewswire)
Oct-27-22 10:02AM	NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 10:01AM	Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-18-22 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-22 08:34AM	Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock? (Zacks) -7.27%

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sandrock Alfred	President and CEO	Apr 02 '24	Sale	9.86	12,115	119,454	322,839	Apr 03 04:10 PM
Swartz Robin	Chief Operating Officer	Apr 02 '24	Sale	9.88	1,357	13,407	117,004	Apr 03 04:13 PM
Sandrock Alfred	President and CEO	Feb 21 '24	Sale	7.46	13,033	97,226	334,954	Feb 22 04:34 PM
Swartz Robin	Chief Operating Officer	Feb 21 '24	Sale	7.45	3,966	29,547	118,361	Feb 22 04:36 PM
PFREUNDSCHUH PETER P.	Chief Financial Officer	Feb 21 '24	Sale	7.46	3,764	28,079	175,669	Feb 22 04:32 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 21 '24	Sale	7.47	3,365	25,137	87,627	Feb 22 04:30 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 20 '24	Sale	7.68	602	4,623	90,992	Feb 22 04:30 PM
Swartz Robin	Chief Operating Officer	Jan 17 '24	Sale	7.15	2,543	18,182	72,327	Jan 19 04:34 PM
Carter Todd Alfred	Chief Scientific Officer	Jan 17 '24	Sale	7.18	1,266	9,090	53,094	Jan 19 04:32 PM
PFREUNDSCHUH PETER P.	Chief Financial Officer	Oct 03 '23	Sale	6.99	13,567	94,833	149,433	Oct 05 04:41 PM
Carter Todd Alfred	Chief Scientific Officer	Sep 15 '23	Option Exercise	2.85	5,000	14,250	64,860	Sep 18 04:44 PM
Carter Todd Alfred	Chief Scientific Officer	Sep 15 '23	Sale	8.16	10,500	85,680	54,360	Sep 18 04:44 PM
Carter Todd Alfred	Chief Scientific Officer	Jul 06 '23	Sale	10.80	5,500	59,400	59,860	Jul 10 04:42 PM

Open in Screener

RVMD

Revolution Medicines Inc

May 02 • 11:28AM ET

39.04

Dollar change +0.22
Percentage change 0.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

RVMD Revolution Medicines Inc daily Stock Chart

Held by: VTI VB IWM VBK VXF IBB IWO SCHA VTWO IWN

Index	RUT	P/E	-	EPS (ttm)	-3.77	Insider Own	17.12%	Shs Outstand	164.67M	Perf Week	10.49%
Market Cap	6.66B	Forward P/E	-	EPS next Y	-3.41	Insider Trans	-0.47%	Shs Float	141.30M	Perf Month	24.36%
Income	-436.37M	PEG	-	EPS next Q	-0.75	Inst Own	76.46%	Short Float	8.84%	Perf Quarter	38.13%
Sales	11.58M	P/S	574.73	EPS this Y	17.83%	Inst Trans	8.22%	Short Ratio	8.35	Perf Half Y	97.15%
Book/sh	11.09	P/B	3.52	EPS next Y	-7.55%	ROA	-29.82%	Short Interest	12.49M	Perf Year	67.18%
Cash/sh	10.87	P/C	3.59	EPS next 5Y	-	ROE	-34.75%	52W Range	15.44 - 39.49	Perf YTD	36.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-22.89%	52W High	-1.15%	Beta	1.45
Dividend TTM	-	Quick Ratio	13.06	Sales past 5Y	11.11%	Gross Margin	19.61%	52W Low	152.82%	ATR (14)	1.62
Dividend Ex-Date	-	Current Ratio	13.06	EPS Y/Y TTM	-21.72%	Oper. Margin	-4207.12%	RSI (14)	68.51	Volatility	4.21% 5.42%
Employees	378	Debt/Eq	0.05	Sales Y/Y TTM	-67.27%	Profit Margin	-3768.28%	Recom	1.07	Target Price	41.62
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-80.53%	Payout	-	Rel Volume	0.29	Prev Close	38.82
Sales Surprise	11.29%	EPS Surprise	-33.66%	Sales Q/Q	-95.16%	Earnings	May 08 AMC	Avg Volume	1.50M	Price	39.04
SMA20	10.21%	SMA50	19.11%	SMA200	36.36%	Trades		Volume	148,557	Change	0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50
Mar-09-20	Initiated	Cowen	Outperform

Show Previous Ratings

May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
05:20PM	Loading…
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Loading…
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
07:01AM	Loading…
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)
May-01-23 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 (GlobeNewswire)
10:01AM	Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-23 07:15AM	Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy (Simply Wall St.)
Apr-13-23 04:05PM	Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.83%
Apr-06-23 07:00AM	Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-22-23 11:29AM	Revolution Medicines (NASDAQ:RVMD investor three-year losses grow to 18% as the stock sheds US$171m this past week (Simply Wall St.)
Mar-11-23 03:27AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 04:02PM	Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-02-23 09:15PM	Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock (GlobeNewswire) -11.72%
Mar-01-23 04:17PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-27-23 06:25PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-21-23 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023 (GlobeNewswire)
Feb-02-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice (Zacks)
07:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-23 05:31AM	Insiders sitting comfortably on a US$376k profit after buying Revolution Medicines, Inc. (NASDAQ:RVMD) stock worth US$1.0m last year (Simply Wall St.)
Jan-12-23 03:25AM	Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength? (Zacks) +11.12%
Jan-03-23 07:00AM	Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 06:15AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-26-22 08:14AM	We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely (Simply Wall St.)
Dec-19-22 07:00AM	Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor (GlobeNewswire) -9.42%
Dec-08-22 06:19AM	Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration (Benzinga)
Dec-07-22 04:05PM	Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofis Termination of SHP2 Inhibitor Development and Commercialization Collaboration (GlobeNewswire)
Nov-10-22 05:48AM	Institutional owners may consider drastic measures as Revolution Medicines, Inc.'s (NASDAQ:RVMD) recent US$110m drop adds to long-term losses (Simply Wall St.) +13.34%
Nov-09-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-22 05:55PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-02-22 10:01AM	Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
09:54AM	Harvard University Stock Portfolio: Top 10 Picks (Insider Monkey)
Nov-01-22 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022 (GlobeNewswire)
Oct-24-22 11:07AM	Who Doesnt Like a Bargain?: Oppenheimer Suggests 2 Stocks to Buy (TipRanks)
Oct-13-22 11:05AM	Loss-making Revolution Medicines (NASDAQ:RVMD) sheds a further US$68m, taking total shareholder losses to 33% over 1 year (Simply Wall St.)
Sep-22-22 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Companys First Mutant-Selective RAS(ON) Inhibitor (GlobeNewswire) +5.44%
Sep-01-22 04:05PM	Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire (GlobeNewswire)
Aug-31-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know (Zacks) +8.21%
Aug-10-22 08:35AM	Need To Know: Analysts Are Much More Bullish On Revolution Medicines, Inc. (NASDAQ:RVMD) Revenues (Simply Wall St.)
Aug-09-22 06:15PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-28-22 04:02PM	Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022 (GlobeNewswire)
Jul-22-22 04:02PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.30%
Jul-19-22 10:41PM	Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock (GlobeNewswire) +7.71%
04:01PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
07:16AM	Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-13-22 07:00AM	Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors (GlobeNewswire)
Jun-28-22 07:00AM	Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236 (GlobeNewswire) -5.41%
Jun-24-22 09:42AM	Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jun-09-22 04:02PM	Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-11-22 06:22AM	What You Need To Know About The Revolution Medicines, Inc. (NASDAQ:RVMD) Analyst Downgrade Today (Simply Wall St.) -7.66%

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sushil	Director	Apr 10 '24	Option Exercise	16.80	2,155	36,204	17,855	Apr 12 04:23 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.33	10,000	353,346	30,424	Apr 12 08:08 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.48	7,500	266,122	452,879	Apr 12 08:08 PM
Patel Sushil	Director	Apr 10 '24	Sale	37.00	2,155	79,735	15,700	Apr 12 04:23 PM
Cislini Jeff	General Counsel	Mar 27 '24	Sale	30.99	1,500	46,481	54,374	Mar 28 04:11 PM
GOLDSMITH MARK A	See Remarks	Mar 18 '24	Sale	31.58	5,788	182,804	460,379	Mar 20 04:44 PM
Horn Margaret A	Chief Operating Officer	Mar 18 '24	Sale	31.58	2,914	92,033	139,553	Mar 20 04:44 PM
Kelsey Stephen Michael	See Remarks	Mar 18 '24	Sale	31.58	2,123	67,051	270,909	Mar 20 04:45 PM
Anders Jack	Chief Financial Officer	Mar 18 '24	Sale	31.58	1,261	39,826	101,959	Mar 20 04:43 PM
Cislini Jeff	General Counsel	Mar 18 '24	Sale	31.58	1,252	39,542	55,874	Mar 20 04:45 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Option Exercise	4.09	7,936	32,458	150,403	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Sale	34.07	7,936	270,345	142,467	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Option Exercise	4.09	15,735	64,356	158,202	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Sale	34.02	15,735	535,306	142,467	Mar 13 04:32 PM
Cislini Jeff	General Counsel	Jan 22 '24	Sale	27.00	1,500	40,500	36,126	Jan 24 04:12 PM
Kelsey Stephen Michael	See Remarks	Jan 08 '24	Sale	29.01	3,337	96,809	221,632	Jan 10 04:26 PM
Kelsey Stephen Michael	See Remarks	Jan 02 '24	Sale	29.10	13,330	387,884	224,969	Jan 04 04:06 PM
Kelsey Stephen Michael	See Remarks	Dec 27 '23	Sale	29.01	33,334	966,996	238,299	Dec 29 04:14 PM
GOLDSMITH MARK A	See Remarks	Dec 18 '23	Sale	25.90	8,165	211,488	376,167	Dec 20 05:08 PM
Horn Margaret A	Chief Operating Officer	Dec 18 '23	Sale	25.90	2,993	77,524	101,467	Dec 19 07:30 PM
Kelsey Stephen Michael	See Remarks	Dec 18 '23	Sale	25.90	2,088	54,083	271,633	Dec 20 05:07 PM
Anders Jack	Chief Financial Officer	Dec 18 '23	Sale	25.90	1,775	45,976	76,416	Dec 20 05:10 PM
Cislini Jeff	General Counsel	Dec 18 '23	Sale	25.90	1,229	31,833	37,284	Dec 20 05:08 PM
Horn Margaret A	Chief Operating Officer	Dec 15 '23	Option Exercise	4.09	5,000	20,450	109,460	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 15 '23	Sale	26.64	5,000	133,183	104,460	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 06 '23	Option Exercise	4.09	5,000	20,450	109,460	Dec 08 04:08 PM
Horn Margaret A	Chief Operating Officer	Dec 06 '23	Sale	25.00	5,000	125,000	104,460	Dec 08 04:08 PM
Cislini Jeff	General Counsel	Nov 20 '23	Sale	21.70	1,500	32,545	38,513	Nov 20 06:24 PM
Horn Margaret A	Chief Operating Officer	Oct 25 '23	Option Exercise	0.54	7,500	4,050	104,460	Oct 25 06:20 PM
GOLDSMITH MARK A	See Remarks	Oct 24 '23	Option Exercise	0.49	35,000	17,150	384,332	Oct 24 07:21 PM
Anders Jack	Chief Financial Officer	Oct 23 '23	Option Exercise	2.98	24,524	72,967	78,191	Oct 23 06:01 PM
Horn Margaret A	Chief Operating Officer	Oct 16 '23	Option Exercise	4.09	25,000	102,250	121,960	Oct 18 04:23 PM
Horn Margaret A	Chief Operating Officer	Oct 16 '23	Sale	33.95	25,000	848,806	96,960	Oct 18 04:23 PM
Kelsey Stephen Michael	See Remarks	Oct 11 '23	Sale	29.05	16,667	484,130	273,721	Oct 13 04:20 PM
Cislini Jeff	General Counsel	Sep 28 '23	Sale	28.20	2,000	56,394	40,013	Oct 02 04:12 PM
GOLDSMITH MARK A	See Remarks	Sep 18 '23	Sale	31.31	8,054	252,175	349,332	Sep 20 04:12 PM
Horn Margaret A	Chief Operating Officer	Sep 18 '23	Sale	31.31	2,514	78,715	96,960	Sep 19 04:17 PM
Kelsey Stephen Michael	See Remarks	Sep 18 '23	Sale	31.31	2,060	64,500	290,388	Sep 20 04:13 PM
Anders Jack	Chief Financial Officer	Sep 18 '23	Sale	31.31	1,427	44,680	53,667	Sep 20 04:11 PM
Cislini Jeff	General Counsel	Sep 18 '23	Sale	31.31	1,214	38,011	42,013	Sep 20 04:11 PM
Horn Margaret A	Chief Operating Officer	Sep 15 '23	Option Exercise	4.09	5,000	20,450	104,474	Sep 19 04:17 PM
Horn Margaret A	Chief Operating Officer	Sep 15 '23	Sale	32.08	5,000	160,408	99,474	Sep 19 04:17 PM
Weber Barbara	Director	Sep 01 '23	Option Exercise	3.80	15,000	57,037	30,825	Sep 06 08:03 PM
Anders Jack	Chief Financial Officer	Sep 01 '23	Option Exercise	2.68	20,000	53,600	75,094	Sep 06 08:02 PM
GOLDSMITH MARK A	See Remarks	Sep 01 '23	Option Exercise	0.77	30,000	23,164	387,386	Sep 06 08:05 PM
GOLDSMITH MARK A	See Remarks	Sep 01 '23	Sale	35.05	30,000	1,051,563	357,386	Sep 06 08:05 PM
Anders Jack	Chief Financial Officer	Sep 01 '23	Sale	35.05	20,000	701,092	55,094	Sep 06 08:02 PM
Weber Barbara	Director	Sep 01 '23	Sale	35.07	15,000	526,000	15,825	Sep 06 08:03 PM
GOLDSMITH MARK A	See Remarks	Sep 01 '23	Sale	35.04	10,000	350,410	35,424	Sep 06 08:05 PM
Horn Margaret A	Chief Operating Officer	Aug 31 '23	Option Exercise	4.09	10,000	40,900	109,474	Sep 01 04:16 PM
Horn Margaret A	Chief Operating Officer	Aug 31 '23	Sale	34.05	10,000	340,458	99,474	Sep 01 04:16 PM
Horn Margaret A	Chief Operating Officer	Aug 15 '23	Option Exercise	4.09	5,000	20,450	104,474	Aug 17 04:17 PM
Horn Margaret A	Chief Operating Officer	Aug 15 '23	Sale	30.53	5,000	152,632	99,474	Aug 17 04:17 PM
Kelsey Stephen Michael	See Remarks	Aug 02 '23	Sale	32.40	16,666	539,978	292,448	Aug 03 04:17 PM
Kelsey Stephen Michael	See Remarks	Aug 01 '23	Sale	29.19	16,666	486,502	309,114	Aug 03 04:17 PM
Cislini Jeff	General Counsel	Jul 31 '23	Sale	26.02	1,500	39,030	43,227	Aug 01 06:23 PM
Kelsey Stephen Michael	See Remarks	Jun 20 '23	Sale	24.89	2,102	52,321	325,780	Jun 22 04:26 PM
Horn Margaret A	Chief Operating Officer	Jun 20 '23	Sale	24.89	2,102	52,321	99,474	Jun 22 04:26 PM
Cislini Jeff	General Counsel	Jun 20 '23	Sale	25.14	1,239	31,148	44,727	Jun 22 04:24 PM
Anders Jack	Chief Financial Officer	Jun 20 '23	Sale	24.89	1,249	31,089	55,094	Jun 22 04:25 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

VYGR

Voyager Therapeutics Inc

RVMD

Revolution Medicines Inc

Upgrade your FINVIZ experience